Japan Mulls Importing Enough H1N1 Vaccine To Treat 20 Million
This article was originally published in PharmAsia News
Executive Summary
Japan might import enough H1N1 vaccines to treat as many as 20 million people in advance of epidemics that could break out in the fall or winter. The Health Ministry is trying to work out the proper number of doses, fearing it could need enough for 53 million if the government is to cover most elderly people. The ministry expects to make its decision by the end of July on how many of the elderly are to be given priority for vaccinations. (Click here for more
You may also be interested in...
At-Home Health Testing Demand Is High Post-Pandemic, But So Are Barriers To Development And Use
At the recent Precision Med-Tri Con conference, laboratory experts traded views on the expansion of at-home testing for disease diagnosis and personalized health insights. While strong consumer demand spells opportunity, there are significant concerns about the accuracy and reliability of home-testing platforms, misuse, accessibility, and lack of health literacy.
Simplified Clinical Trial Transparency Rules To Go Live In The EU In June
A new version of the EU Clinical Trials Information System’s public portal will integrate the functionalities of the streamlined transparency rules.
Top-Selling Drugs 2023: Pharma’s $60bn COVID-19 Cliff
Pfizer/BioNTech’s COVID-19 vaccine Comirnaty toppled after recording the highest ever annual sales for a pharmaceutical in 2022, while Novo Nordisk’s Ozempic climbed rapidly. But Merck & Co’s immuno-oncology blockbuster Keytruda was secure in the number one spot in 2023 as COVID-19 receded.